Changes in food noise during GLP-1 treatment came up in interviews with 30 current and former users [1]. Participants described less appetite or fewer thoughts about food. They also described side effects, treatment costs and differences in support.
What people reported
Our summary of why people start treatment covers a separate survey of recent tirzepatide users. In the interviews described here, 23 participants were using a GLP-1 drug and seven had stopped. Some described the appetite change as making it easier to change habits. Others reported adverse effects or difficulty getting and paying for medication [1].
Researchers also coded posts from one Wegovy forum (n = 660) [2]. About 29% were coded for efficacy and 13% for managing side effects. Those shares describe discussion topics, and readers cannot use them to estimate symptom frequency.
How to interpret these accounts
Evidence on GLP-1 side effects in trials measures reported events within defined treatment groups. Interview studies instead show how people described managing symptoms and deciding whether a treatment was worthwhile. Our review of GLP-1 stigma experiments examines how others rated fictional people using medication. Those experiments measure a different outcome from the experiences patients reported in interviews.
Participants also described perceived stigma and uneven support [1]. These studies illustrate experiences people may want to discuss with a clinician. They cannot predict how an individual will feel on a particular medicine.